<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019379</url>
  </required_header>
  <id_info>
    <org_study_id>1809583731</org_study_id>
    <nct_id>NCT04019379</nct_id>
  </id_info>
  <brief_title>Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease</brief_title>
  <official_title>Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Purdue University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to develop a method for simultaneous whole-body calcium and phosphorus
      balance and full kinetic modeling of both ions in patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional calcium absorption</measure>
    <time_frame>48 hours</time_frame>
    <description>Determined by kinetic modeling of serum and urine Ca-44 isotope after oral and IV isotope administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional phosphorus absorption</measure>
    <time_frame>48 hours</time_frame>
    <description>Determined by kinetic modeling of serum and urine P-33 isotope after oral and IV isotope administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium balance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determined by analysis of calcium content in complete 24-hour urine and stool collections, subtracted from the diet calcium content consumed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorus balance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determined by analysis of phosphorus content in complete 24-hour urine and stool collections, subtracted from the diet phosphorus content consumed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium kinetic model</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determined by kinetic modeling of serum, urine, and fecal Ca-44 isotope after oral and IV isotope administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorus kinetic model</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determined by kinetic modeling of serum, urine, and fecal P-33 isotope after oral and IV isotope administrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance rate</measure>
    <time_frame>24 hours, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma fibroblast growth factor 23 concentration</measure>
    <time_frame>Day 1, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma parathyroid hormone concentration</measure>
    <time_frame>Day 1, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1,25-dihydroxyvitamin D concentration</measure>
    <time_frame>Day 1, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma phosphate concentration</measure>
    <time_frame>Day 1, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma calcium concentration</measure>
    <time_frame>Day 1, Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Phosphorus and Calcium Disorders</condition>
  <condition>Chronic Kidney Disease Mineral and Bone Disorder</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Ca/High Phos crossover to Low Ca/Low Phos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Ca/Low Phos crossover to Low Ca/High Phos</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Calcium/High Phosphorus Diet</intervention_name>
    <description>Controlled research diet of low calcium/high phosphorus</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Calcium/Low Phosphorus Diet</intervention_name>
    <description>Controlled research diet of high calcium/low phosphorus</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women, ages 30-75 years old, any race or ethnicity

          -  Moderate chronic kidney disease

          -  Female subjects must be postmenopausal (&gt;12 months since last menstrual period),
             surgically sterile, or confirmed not pregnant by pregnancy test

          -  Must be on stable doses of medications (except those noted in exclusion criteria) for
             at least 4 weeks prior to the study

          -  Willing to discontinue nutritional supplements (e.g. vitamin D, calcium,
             multivitamin/minerals, or others) upon enrollment until completion of the study

          -  Adequate vitamin D status defined as serum 25D &gt; 20 ng/mL

        Exclusion Criteria:

          -  Plans to initiate dialysis within 6 months

          -  Hypercalcemia defined as serum calcium &gt;10.5 mg/dL within past 3 months

          -  Hyperkalemia defined as serum potassium &gt;5.5 mg/dL within past 3 months

          -  Hyperphosphatemia defined as serum phosphate &gt;5.5 mg/dL within past 3 months

          -  Intestinal disease that alters absorption or normal intestinal function including
             celiac disease, small bowel resection, or bariatric surgery

          -  Serious, uncontrolled underlying systemic disease including diabetes, lupus,
             hypertension

          -  Pregnant or breastfeeding

          -  Prescribed a phosphate binder medication, calcitriol, vitamin D analogs,
             calcimimetics, parathyroid hormone analogues, and other medications that may alter Ca
             and P metabolism within past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Hill Gallant, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Purdue University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen M Hill Gallant, PhD</last_name>
    <phone>765-494-0101</phone>
    <email>hillgallant@purdue.edu</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Purdue University</investigator_affiliation>
    <investigator_full_name>Kathleen Hill Gallant</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Whole-body balance</keyword>
  <keyword>Kinetic modeling</keyword>
  <keyword>Intestinal absorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

